vs
Side-by-side financial comparison of Lifevantage Corp (LFVN) and STEM, INC. (STEM). Click either name above to swap in a different company.
Lifevantage Corp is the larger business by last-quarter revenue ($48.9M vs $47.1M, roughly 1.0× STEM, INC.). Lifevantage Corp runs the higher net margin — 0.6% vs -33.9%, a 34.5% gap on every dollar of revenue. On growth, STEM, INC. posted the faster year-over-year revenue change (-15.6% vs -27.8%). Over the past eight quarters, STEM, INC.'s revenue compounded faster (36.1% CAGR vs 0.7%).
Lifevantage Corp is a health and wellness enterprise that develops, manufactures and distributes science-backed nutritional supplements, skincare and personal care products. It operates via a direct-to-consumer network marketing model, serving customers across North America, Europe and the Asia-Pacific, with focus on anti-aging and holistic health solution segments.
StemCells, Inc. is a public biopharmaceutical company headquartered in Newark, California, that is developing purified human neural stem cells (HuCNS-SCs) in the hopes of treating central nervous system disorders and paralysis. StemCells' HuCNS-SCs have the ability to differentiate into the three main types of cells found in the central nervous system: neurons, astrocytes and oligodendrocytes.
LFVN vs STEM — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $48.9M | $47.1M |
| Net Profit | $276.0K | $-16.0M |
| Gross Margin | 74.0% | 48.9% |
| Operating Margin | 1.0% | -17.7% |
| Net Margin | 0.6% | -33.9% |
| Revenue YoY | -27.8% | -15.6% |
| Net Profit YoY | -89.2% | 68.8% |
| EPS (diluted) | $0.02 | $-4.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $48.9M | $47.1M | ||
| Q3 25 | $47.6M | $38.2M | ||
| Q2 25 | $55.1M | $38.4M | ||
| Q1 25 | $58.4M | $32.5M | ||
| Q4 24 | $67.8M | $55.8M | ||
| Q3 24 | $47.2M | $29.3M | ||
| Q2 24 | $48.9M | $34.0M | ||
| Q1 24 | $48.2M | $25.5M |
| Q4 25 | $276.0K | $-16.0M | ||
| Q3 25 | $2.2M | $-23.8M | ||
| Q2 25 | $2.0M | $202.5M | ||
| Q1 25 | $3.5M | $-25.0M | ||
| Q4 24 | $2.5M | $-51.1M | ||
| Q3 24 | $1.8M | $-148.3M | ||
| Q2 24 | $1.3M | $-582.3M | ||
| Q1 24 | $1.7M | $-72.3M |
| Q4 25 | 74.0% | 48.9% | ||
| Q3 25 | 79.5% | 35.5% | ||
| Q2 25 | 79.9% | 33.4% | ||
| Q1 25 | 81.0% | 32.4% | ||
| Q4 24 | 80.5% | -4.4% | ||
| Q3 24 | 79.9% | 21.2% | ||
| Q2 24 | 79.5% | 27.6% | ||
| Q1 24 | 78.9% | -95.0% |
| Q4 25 | 1.0% | -17.7% | ||
| Q3 25 | 4.8% | -33.6% | ||
| Q2 25 | 3.9% | -34.8% | ||
| Q1 25 | 6.9% | -65.0% | ||
| Q4 24 | 5.1% | -84.4% | ||
| Q3 24 | 5.4% | -493.2% | ||
| Q2 24 | 5.9% | -1705.5% | ||
| Q1 24 | 4.0% | -267.0% |
| Q4 25 | 0.6% | -33.9% | ||
| Q3 25 | 4.5% | -62.2% | ||
| Q2 25 | 3.6% | 527.8% | ||
| Q1 25 | 5.9% | -76.9% | ||
| Q4 24 | 3.8% | -91.6% | ||
| Q3 24 | 3.9% | -506.3% | ||
| Q2 24 | 2.7% | -1712.6% | ||
| Q1 24 | 3.4% | -283.9% |
| Q4 25 | $0.02 | $-4.40 | ||
| Q3 25 | $0.17 | $-2.84 | ||
| Q2 25 | $0.16 | $-1.79 | ||
| Q1 25 | $0.26 | $-0.15 | ||
| Q4 24 | $0.19 | $-15.29 | ||
| Q3 24 | $0.14 | $-18.24 | ||
| Q2 24 | $0.10 | $-71.81 | ||
| Q1 24 | $0.13 | $-0.46 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $48.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $33.0M | $-249.4M |
| Total Assets | $61.2M | $308.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $48.9M | ||
| Q3 25 | — | $43.1M | ||
| Q2 25 | $20.2M | $40.8M | ||
| Q1 25 | — | $58.6M | ||
| Q4 24 | — | $56.3M | ||
| Q3 24 | — | $75.4M | ||
| Q2 24 | $16.9M | $89.6M | ||
| Q1 24 | — | $112.8M |
| Q4 25 | $33.0M | $-249.4M | ||
| Q3 25 | $33.2M | $-235.7M | ||
| Q2 25 | $34.6M | $-214.1M | ||
| Q1 25 | $34.0M | $-417.5M | ||
| Q4 24 | $29.9M | $-398.4M | ||
| Q3 24 | $27.7M | $-344.1M | ||
| Q2 24 | $26.0M | $-203.2M | ||
| Q1 24 | $26.8M | $371.6M |
| Q4 25 | $61.2M | $308.9M | ||
| Q3 25 | $61.6M | $362.6M | ||
| Q2 25 | $72.0M | $379.2M | ||
| Q1 25 | $77.2M | $405.1M | ||
| Q4 24 | $68.5M | $437.4M | ||
| Q3 24 | $61.5M | $537.8M | ||
| Q2 24 | $60.3M | $691.5M | ||
| Q1 24 | $61.3M | $1.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.8M | $8.2M |
| Free Cash FlowOCF − Capex | $1.7M | — |
| FCF MarginFCF / Revenue | 3.5% | — |
| Capex IntensityCapex / Revenue | 2.2% | — |
| Cash ConversionOCF / Net Profit | 10.11× | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.8M | $8.2M | ||
| Q3 25 | $-2.3M | $11.4M | ||
| Q2 25 | $1.0M | $-21.3M | ||
| Q1 25 | $2.2M | $8.5M | ||
| Q4 24 | $9.2M | $-14.7M | ||
| Q3 24 | $-583.0K | $-9.4M | ||
| Q2 24 | $2.6M | $-11.9M | ||
| Q1 24 | $3.1M | $-621.0K |
| Q4 25 | $1.7M | — | ||
| Q3 25 | $-2.7M | — | ||
| Q2 25 | $835.0K | — | ||
| Q1 25 | $1.9M | — | ||
| Q4 24 | $8.7M | — | ||
| Q3 24 | $-932.0K | — | ||
| Q2 24 | $2.3M | — | ||
| Q1 24 | $2.8M | — |
| Q4 25 | 3.5% | — | ||
| Q3 25 | -5.8% | — | ||
| Q2 25 | 1.5% | — | ||
| Q1 25 | 3.2% | — | ||
| Q4 24 | 12.8% | — | ||
| Q3 24 | -2.0% | — | ||
| Q2 24 | 4.7% | — | ||
| Q1 24 | 5.8% | — |
| Q4 25 | 2.2% | — | ||
| Q3 25 | 0.9% | — | ||
| Q2 25 | 0.4% | — | ||
| Q1 25 | 0.6% | — | ||
| Q4 24 | 0.7% | — | ||
| Q3 24 | 0.7% | — | ||
| Q2 24 | 0.6% | — | ||
| Q1 24 | 0.6% | — |
| Q4 25 | 10.11× | — | ||
| Q3 25 | -1.07× | — | ||
| Q2 25 | 0.53× | -0.11× | ||
| Q1 25 | 0.64× | — | ||
| Q4 24 | 3.61× | — | ||
| Q3 24 | -0.32× | — | ||
| Q2 24 | 1.98× | — | ||
| Q1 24 | 1.86× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
